Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH

NCT03556020 | Terminated Phase 2 DMC FDA Drug

• 1 other identifier: PB1046-PT-CL-0004
• Study Type: interventional
• Target: 35
• Locations: 1 country
• Sites: 26

Brief Summary

This is a multi-center, randomized, double-blind, controlled, Phase 2 study to assess the safety, tolerability, and efficacy of pemziviptadil (PB1046) at the optimally titrated dose after 16 weeks of treatment. Subjects will be randomized in a 2:1 ratio to one of two parallel dose groups: a) high-dose group where PB1046 will be up-titrated from a 0.2 mg/kg minimally effective starting dose to a target high dose level of at least 1.2 mg/kg or higher to a maximally tolerated dose (MTD), or b) a low-dose group that will start at 0.2 mg/kg and remain at this minimally effective dose (MED) level with sham up-titration. The total treatment period will be comprised of 2 phases: 1) an initial 10 week dose titration phase in which weekly doses of PB1046 will be titrated (or sham titrated) up to a target dose level of at least 1.2 mg/kg or higher to the MTD, and 2) a maintenance of treatment phase that begins when subjects reach week 11 and continues for 6 weeks during which no further up-titration should occur.

Conditions

Pulmonary Arterial Hypertension

Outcome Measures

Primary Outcomes (10)

• Incidence and severity of AEs

  172 days - Starting up to 30 days prior to first dose and completing 28 days after last dose.

• Incidence of Clinical Laboratory Abnormalities

  172 days - Starting up to 30 days prior to first dose and completing 28 days after last dose.

• Changes in Diastolic Blood Pressure

  172 days - Starting up to 30 days prior to first dose and completing 28 days after last dose.

• Changes in Systolic Blood Pressure

  172 days - Starting up to 30 days prior to first dose and completing 28 days after last dose.

• Changes in Oral Body Temperature

  172 days - Starting up to 30 days prior to first dose and completing 28 days after last dose.

• Changes in Respiratory Rate

  172 days - Starting up to 30 days prior to first dose and completing 28 days after last dose.

• Changes in Heart Rate

  172 days - Starting up to 30 days prior to first dose and completing 28 days after last dose.

• 12-Lead ECG - Incidence of clinically significant findings

  172 days - Starting up to 30 days prior to first dose and completing 28 days after last dose.

• Immunogenicity

  172 days - Starting up to 30 days prior to first dose and completing 8 weeks after last dose. May be extended in the event that result does not return to baseline in time allotted.

• Change in baseline in pulmonary vascular resistance (PVR)

  142 days - Pre-dose (up to 30 days prior to first dose) and post-dose 16.

Secondary Outcomes (8)

• Change from baseline in 6MWD

  142 days - Pre-dose (up to 30 days prior to first dose) and one week post-dose 16.

• Change from baseline in NT-proBNP

  142 days - Pre-dose (up to 30 days prior to first dose) and one week post-dose 16.

• Change from baseline in cardiac index (CI)

  142 days - Pre-dose (up to 30 days prior to first dose) and one week post-dose 16.

• Change from baseline in mean pulmonary artery pressure (mPAP)

  142 days - Pre-dose (up to 30 days prior to first dose) and one week post-dose 16.

• Change from baseline in mean right atrial pressure (mRAP)

  142 days - Pre-dose (up to 30 days prior to first dose) and one week post-dose 16.

Other Outcomes (12)

• Change from baseline in Borg Dyspnea Index (BDI) at the end of treatment

  142 days - Pre-dose (up to 30 days prior to first dose) and one week post-dose 16.

• Change from baseline in emPHasis-10 (HRQoL) score at the end of treatment

  142 days - Pre-dose (up to 30 days prior to first dose) and one week post-dose 16.

• Change in NYHA/WHO Functional Class (FC) at the end of treatment

  142 days - Pre-dose (up to 30 days prior to first dose) and one week post-dose 16.

Study Arms (2)

High Dose Group

EXPERIMENTAL

Maximally tolerated dose Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection

Drug: Pemziviptadil (PB1046)

Low Dose Group

EXPERIMENTAL

Minimally effective dose Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection

Drug: Pemziviptadil (PB1046)

Interventions

Pemziviptadil (PB1046) DRUG

Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection

High Dose Group; Low Dose Group

Eligibility Criteria

• Age: 18 Years - 79 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female subjects with PAH, ≥18 and ≤ 79 years of age, who are symptomatic and have reduced exercise capacity due primarily to their PAH diagnosis and have been assessed by a qualified individual (i.e. physician, physician assistant, nurse practitioner) to be in NYHA/WHO functional class II or III;
• Willing and able to sign a written informed consent prior to all study-related procedures;
• Subjects with PAH belonging to one of the following subgroups of the Nice Clinical Classification of Pulmonary Hypertension Group 1: a. Idiopathic, b. Heritable, c. Drug or toxin-induced, d. Associated with connective tissue disease, HIV infection, portal hypertension, congenital heart disease (pulmonary-to-systemic shunt;
• Two 6MWD test results \> 50 m and \< 550 m prior to randomization with results +/- 10% of each other. Note: Up to four tests may be conducted between Screening and Randomization for eligibility purposes;
• Hemodynamic assessment of PAH demonstrating elevated mPAP and PVR as indicated below during the Screening Period: a. mean pulmonary artery pressure (mPAP) of ≥ 25 mmHg; and, b. pulmonary vascular resistance (PVR) ≥ 400 dyne•sec/cm5; and, c. pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) of ≤ 12 mmHg if PVR ≥ 400 and \< 500 dynes•sec/cm5; or PCWP/LVEDP ≤ 15 mmHg if PVR ≥ 500 dynes•sec/cm5;
• Body mass index ≥ 18 kg/m2 and ≤ 40 kg/m2 at screening;
• Meet the following criteria determined by pulmonary function tests completed no more than 24 weeks prior to screening: a. Forced expiratory volume in one second (FEV1) ≥ 55% of predicted normal, b. FEV1: FVC (forced vital capacity) ratio ≥ 0.60;
• Agrees to use a medically acceptable method of contraception (both male and female patients) throughout the entire study period and continuing for 30 days after their last dose of study drug;
• Stable background medical regimen of up to 3 oral PAH therapies for at least 30 days prior to Screening and having been on PAH therapy for at least 3 months;
• If a subject has historical diagnosis (prior to screening visit) of being positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV), must be clinically stable and if on therapy, must be on stable therapy for HIV or HCV for at least 3 months; Willing and able to understand and follow instructions; return to the study unit for specified study visits; and able to participate in the study for the entire period.

You may not qualify if:

• Concomitant medical disorder, condition, or history, that in the opinion of the Investigator would impair the subject's ability to participate in or complete the requirements of the study;
• Concomitant medical disorder that is expected to limit the subject's life-expectancy to ≤ 1 year;
• Pregnant or lactating female subjects;
• First positive result from serology testing at visit 1 (screening labs) for HIV, HBsAg, or HCV prior to randomization;
• Participation in another investigational drug study within 30 days prior to screening or participating in a non-medication study which, in the opinion of the Investigator, would interfere with the study compliance or outcome assessments;
• Use of chronic subcutaneous prostanoid/prostacyclin therapy for PAH within 30 days prior to screening, including prostacyclin receptor agonists;
• More than mild mitral or aortic valve disease, left ventricular ejection fraction \< 50%, or left ventricular regional wall motion abnormality suggestive of active coronary artery disease on documented 2D-echocardiography occurring within 12 months of Screening;
• Sustained systolic blood pressure (SBP) \< 95 mmHg and/or diastolic blood pressure (DBP) \< 50 mmHg (confirmed by a duplicate seated reading) on at least 3 consecutive readings (self-monitored or office) at screening and prior to dosing, or overt symptomatic hypotension;
• Sustained resting heart rate \>110 beats per minute (BPM) (confirmed by duplicate assessments of office vital signs or consecutive ECG assessments) on at least 3 consecutive readings at screening and prior to dosing;
• Clinically significant renal dysfunction at the Screening Visit as measured by the estimated glomerular filtration rate (eGFR)
• Significant liver dysfunction as measured by any one of the following at screening: a. alanine aminotransferase (ALT) \>3.0 times upper limit of normal (ULN) or; b. aspartate aminotransferase (AST) \>3.0 times ULN or; c. serum bilirubin ≥ 1.6 mg/dL;
• Known history of substance abuse within the past 1 year that in the opinion of the Investigator would impair the subject's ability to participate in or complete the requirements of the study;
• Any major surgical procedure within 90 days prior to screening or planned surgical procedure during the study period;
• Any in-patient hospitalization (defined as greater than 23 hours) within 30 days of subject screening;
• Enrollment within the past 3 months prior to screening or plans to enroll during the study into a cardiopulmonary rehabilitation program;

Sponsors & Collaborators

• PhaseBio Pharmaceuticals Inc.: lead

Study Sites (26)

IMC - Diagnostic & Medical Clinic, LLC

Mobile, Alabama, 36604, United States

Location

Banner University Medical Center

Tucson, Arizona, 85724, United States

Location

University of California, San Diego (UCSD)

La Jolla, California, 92037, United States

Location

University of Southern California, Keck School of Medicine

Los Angeles, California, 90033, United States

Location

VA Greater Los Angeles Healthcare System

Los Angeles, California, 90073, United States

Location

University of California-Davis

Sacramento, California, 95817, United States

Location

University of Colorado Denver

Aurora, Colorado, 80045, United States

Location

University of Florida

Gainesville, Florida, 32610, United States

Location

The University Miami Health Hospital

Miami, Florida, 66160, United States

Location

AdventHealth Orlando

Orlando, Florida, 32803, United States

Location

The Emory Clinic

Atlanta, Georgia, 30322, United States

Location

University of Chicago

Chicago, Illinois, 60637, United States

Location

University of Iowa Hospitals & Clinics, Dept of Internal Medicine

Iowa City, Iowa, 52242, United States

Location

University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

Location

Tufts University

Boston, Massachusetts, 02111, United States

Location

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

Location

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Location

NYU Langone Health

New York, New York, 10016, United States

Location

University of Rochester Medical Center

Rochester, New York, 14642, United States

Location

The Linder Center for Resarch and Education at The Christ Hospital

Cincinnati, Ohio, 45219, United States

Location

University of Cincinnati

Cincinnati, Ohio, 45219, United States

Location

INTEGRIS Baptist Medical Center

Oklahoma City, Oklahoma, 73112, United States

Location

Allegheny General Hospital

Pittsburgh, Pennsylvania, 15212, United States

Location

UPMC Presbyterian Hospital

Pittsburgh, Pennsylvania, 15213, United States

Location

UT Southwestern Medical Center

Dallas, Texas, 75390, United States

Location

Memorial Hermann Hospital CRU affiliated with University of Texas Health Science Center at Houston - McGovern Medical School

Houston, Texas, 77030, United States

Location

MeSH Terms

Conditions

Pulmonary Arterial Hypertension

Interventions

VIP-ELP fusion molecule PB1046

Condition Hierarchy (Ancestors)

Hypertension, Pulmonary; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 1, 2018
• First Posted: June 14, 2018
• Study Start: July 15, 2018
• Primary Completion: January 7, 2022
• Study Completion: January 7, 2022
• Last Updated: August 23, 2022

Record last verified: 2022-08

Locations

US (26)